Cipla Defeated In US Kyprolis Patent Tussle
Three Key US Patents Not Obvious, Court Finds
Indian firm Cipla went it alone against Amgen and its Onyx Therapeutics subsidiary to obtain a judgment that would allow for market entry in the US for the firm’s generic to the Kyprolis oncology brand. However, a district court has ruled in the main against the firm.
